← Leaderboards
Fabio A Recchia
New York Medical College
$8,801,204
Attributed
$11,878,689
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $839.8K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$11,878,689 · 6
By mechanism
R01$9,086,758 · 4
P01$2,791,931 · 2
Top collaborators
- Daniel Patrick Kelly4 shared
- Kenneth Walsh4 shared
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureMyocardialFunctional DisorderHeartCanis FamiliarisCardiacMetabolicMetabolismProductionMolecularInstrumentCellsCardiac MyocytesAttenuatedNovel TherapeuticsMitochondriaProteinsFatty Acid OxidationHemodynamicsBaseEstersGlucoseOxidationResearch Study
Grant awards (25)
Targeting Ketone Metabolism as a Novel Heart Failure Therapy$802,632
R01 · FY2023 · HL
Targeting Ketone Metabolism as a Novel Heart Failure Therapy$802,632
R01 · FY2022 · HL
Targeting Ketone Metabolism as a Novel Heart Failure Therapy$802,315
R01 · FY2021 · HL
Targeting Ketone Metabolism as a Novel Heart Failure Therapy$816,865
R01 · FY2020 · HL
Follistatin-like protein 1 in cardiac and systemic metabolism$695,637
R01 · FY2019 · HL · contact PI
Follistatin-like protein 1 in cardiac and systemic metabolism$713,913
R01 · FY2018 · HL · contact PI
Follistatin-like protein 1 in cardiac and systemic metabolism$742,374
R01 · FY2017 · HL · contact PI
Follistatin-like protein 1 in cardiac and systemic metabolism$778,602
R01 · FY2016 · HL · contact PI
VEGF receptor-1-mediated protection in dilated cardiomyopathy$398,687
R01 · FY2015 · HL · contact PI
VEGF receptor-1-mediated protection in dilated cardiomyopathy$402,632
R01 · FY2014 · HL · contact PI
Substrate Selection and Oxidative Stress in Heart Failure$443,091
P01 · FY2013 · HL · contact PI
VEGF receptor-1-mediated protection in dilated cardiomyopathy$396,755
R01 · FY2013 · HL · contact PI
VEGF receptor-1-mediated protection in dilated cardiomyopathy$435,750
R01 · FY2012 · HL · contact PI
Substrate Selection and Oxidative Stress in Heart Failure$278,845
P01 · FY2012 · HL · contact PI
Substrate Selection and Oxidative Stress in Heart Failure$278,845
P01 · FY2011 · HL · contact PI
Substrate Selection and Oxidative Stress in Heart Failure$278,845
P01 · FY2010 · HL · contact PI
Substrate Selection and Oxidative Stress in Heart Failure$286,658
P01 · FY2009 · HL · contact PI
Metabolic Phenotype Switch in HJeart Failure$336,165
P01 · FY2007 · HL · contact PI
Metabolic Phenotype Switch in HJeart Failure$305,301
P01 · FY2006 · HL · contact PI
Metabolic Phenotype Switch in HJeart Failure$296,408
P01 · FY2005 · HL
Metabolic Phenotype Switch in HJeart Failure$287,773
P01 · FY2004 · HL
CONTROL OF METABOLISM BY NO IN THE FAILING HEART$332,992
R01 · FY2003 · HL
CONTROL OF METABOLISM BY NO IN THE FAILING HEART$323,440
R01 · FY2002 · HL
CONTROL OF METABOLISM BY NO IN THE FAILING HEART$314,165
R01 · FY2001 · HL
CONTROL OF METABOLISM BY NO IN THE FAILING HEART$327,367
R01 · FY2000 · HL